Beta Bionics
Develops autonomous bionic pancreas systems for diabetes management.
Company facts
- Founded
- 2015
- Employees
- 423
- Headquarters
- United States
- Type
- Public
- Listed
- NASDAQ: BBNX
- Subsidiaries
- iLet
About
Beta Bionics is a people-focused medical technology company dedicated to making diabetes easier for everyone, every day. The company was founded with a singular mission: to bring innovative type 1 diabetes management solutions to the many, not the few. At the heart of their innovation is the iLet Bionic Pancreas, the world's first bionic pancreas and the first and only insulin delivery system that does not require carb counting, bolusing, correction factors, or pre-set basal rates. The iLet Bionic Pancreas is an insulin delivery system that reduces the need to make decisions about diabetes management because it makes the decisions for you. Using data from Dexcom CGM or FreeStyle Libre 3 Plus sensors, the iLet continuously learns the user's insulin needs and makes 100% of insulin doses autonomously. The only number needed to get started is a user's weight - the iLet does the rest. Beta Bionics is a public benefit corporation and a certified B Corporation, accountable to operate with high standards of transparency, sustainability, and accountability to customers, employees, and society.